ES2031513T3 - Quinazolindionas y piridopirimidinadionas. - Google Patents

Quinazolindionas y piridopirimidinadionas.

Info

Publication number
ES2031513T3
ES2031513T3 ES198787307311T ES87307311T ES2031513T3 ES 2031513 T3 ES2031513 T3 ES 2031513T3 ES 198787307311 T ES198787307311 T ES 198787307311T ES 87307311 T ES87307311 T ES 87307311T ES 2031513 T3 ES2031513 T3 ES 2031513T3
Authority
ES
Spain
Prior art keywords
aquilil
bencilo
quinazolindionas
piridopirimidinadionas
trifluormetilo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787307311T
Other languages
English (en)
Inventor
John Adams Lowe Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1986/001718 external-priority patent/WO1988001270A1/en
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2031513T3 publication Critical patent/ES2031513T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

QUINAZOLINODIONAS Y PIRIDOPIRIMIDINODIONAS, UTILES COMO AGENTES, ANTIDEPRESIVOS ANTIASMATICOS Y ANALGESICOS DE LA FORMULA (I), Y SUS SALES DE ADICION FARMACEUTICAMENTE ACEPTABLES DONDE R1 ES HIDROGENO, ALQUILO DE 1 A 3 ATOMOS DE C, CICLOPENTILMETILO, CICLOHEXILMETILO, NORBONILMETILO, [2,2,2] BICICLOOCTILMETILO O BENCILO, SIENDO EL FENILO DEL BENCILO OPCIONELMENTE SUSTITUIDO, POR HALOGENO, TRIFLUORMETILO, NITRO, CARBOXI O CO2-M+ DONDE M+ ES UN CATION ACEPTABLE FARMACEUTICAMENTE, Y ES CARBOXI, CARBOALXOI, DONDE EL ALCOXI TIENE 1 A 6 ATOMOS DE C, CARBOBENCILOXI, CARBOXAMIDO, N-ALQUILCARBOXAMIDO, DODNE EL ALQUILO TIENE 1 A 6 ATOMOS DE C, O CO2-M+ ESTA DEFINIDO MAS ARRIBA, Y Z ES N O CH, Y CUANDO Z ES CH, R1 ES BENCILO TETRAZOLILO SUSTITUIDO OPCIONALMENTE POR UN GRUPO SELECCIONADO DESDE ALQUILO DE 1 A 3 ATOMOS DE CARBONO Y BENCILO.
ES198787307311T 1986-08-21 1987-08-19 Quinazolindionas y piridopirimidinadionas. Expired - Lifetime ES2031513T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1986/001718 WO1988001270A1 (en) 1986-08-21 1986-08-21 Pyridopyrimidinediones
US07/076,976 US4797403A (en) 1986-08-21 1987-07-23 Quinazolinediones and pyridopyrimidinediones

Publications (1)

Publication Number Publication Date
ES2031513T3 true ES2031513T3 (es) 1992-12-16

Family

ID=26758725

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787307311T Expired - Lifetime ES2031513T3 (es) 1986-08-21 1987-08-19 Quinazolindionas y piridopirimidinadionas.

Country Status (6)

Country Link
US (1) US4880810A (es)
EP (1) EP0260817B1 (es)
AT (1) ATE63553T1 (es)
DE (1) DE3770095D1 (es)
ES (1) ES2031513T3 (es)
GR (1) GR3002065T3 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
DE4339209A1 (de) * 1993-11-17 1995-05-18 Hoechst Ag Verfahren zur Herstellung von substituierten Chinazolin-2,4-dionen
DE4429978A1 (de) * 1994-08-24 1996-02-29 Bayer Ag Verfahren zur Herstellung von Chinazolin-2,4-dionen
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US5622278A (en) * 1995-11-16 1997-04-22 Fries; Randy L. Ladder caddy
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6037345A (en) * 1998-01-13 2000-03-14 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazolinedione and pyridopyrimidinedione derivatives
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
JP2000119272A (ja) 1998-10-15 2000-04-25 Nippon Zoki Pharmaceut Co Ltd 新規７−アミノピリド〔２，３−ｄ〕ピリミジン誘導体
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
TWI243055B (en) 2000-04-13 2005-11-11 Nippon Zoki Pharmaceutical Co Pharmaceutical composition for use in treatment of dermatitis
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
US20040146561A1 (en) 2001-05-23 2004-07-29 Naoki Sakurai Compositions for promoting healing of bone fracture
CN1537018A (zh) 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) * 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
WO2003086373A1 (en) * 2002-04-12 2003-10-23 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
MXPA04009997A (es) * 2002-04-12 2004-12-13 Celgene Corp Modulacion de la diferenciacion de celulas madre y progenitoras, ensayos y usos de las mismas.
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
WO2009120296A1 (en) * 2008-03-24 2009-10-01 Celgene Corporation Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
BRPI0912103A2 (pt) 2008-05-27 2021-04-20 Astrazeneca Ab derivados de fenoxipiridinilamida e seu uso no tratamento de estados de doenças mediados por pde4
SI3083564T1 (sl) 2013-12-20 2018-10-30 Novartis Ag Derivati heteroarilbutanojske kisline kot inhibitorji LTA4H
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1064259A (en) * 1963-12-19 1967-04-05 Union Pharma Scient Appl New derivatives of 2-anilino-nicotinic acid and process for their preparation
US3794643A (en) * 1971-04-20 1974-02-26 Hisamitsu Pharmaceutical Co Quinazolinedione derivatives
DE2334266A1 (de) * 1972-07-07 1974-01-31 Hisamitsu Pharmaceutical Co Pyrido eckige klammer auf 2,3-d eckige klammer zu pyrimidin-2,4 (1h, 3h)-dione
US3922275A (en) * 1972-11-09 1975-11-25 Hisamitsu Pharmaceutical Co Pyrido{8 2,3-D{9 {0 pyrimidine-2,4(1H,3H)-diones
JPS5069096A (es) * 1973-10-25 1975-06-09
JPS5649917B2 (es) * 1973-12-18 1981-11-25
DE3347526A1 (de) * 1983-12-30 1985-07-11 Troponwerke GmbH & Co KG, 5000 Köln Verfahren zur herstellung substituierter chinazolin-2.4(1h.3h)-dione
US4808587A (en) * 1986-04-16 1989-02-28 Nippon Zoki Pharmaceutical Co., Ltd. 5-substituted pyrido[2,3-d]pyrimidine-2,4-diones
MX7829A (es) * 1986-08-21 1993-08-01 Pfizer Quinazolindionas y piridopirimindionas y procedimiento para su preparacion

Also Published As

Publication number Publication date
DE3770095D1 (de) 1991-06-20
US4880810A (en) 1989-11-14
ATE63553T1 (de) 1991-06-15
GR3002065T3 (en) 1992-12-30
EP0260817A1 (en) 1988-03-23
EP0260817B1 (en) 1991-05-15

Similar Documents

Publication Publication Date Title
ES2031513T3 (es) Quinazolindionas y piridopirimidinadionas.
DK0640592T3 (da) N-acylerede tricycliske azaheteroringe anvendelige som vasopressin-antagonister
AR240929A2 (es) "n-piridinsulfonil-n'-piridinil-y-triazinil-ureas procedimiento parasu preparacion, intermediarios para uso exclusivo en dicho procedimiento, y composiciones que contienen dichas ureas"
ES2051796T3 (es) Procedimiento para preparar derivados de dihidrobenzopiran-2-carboxilatos alcoxi-sustituidos.
BR9305907A (pt) Uso de derivados de substituída para tratamento de esclerose múltipla
ES2032613T3 (es) Procedimiento para la preparacion de derivados de la didehidro-vitamina d3. (reserva del art. 167.2 cpe).
PE91798A1 (es) Pirrolicarboxanilidas condensadas: utiles como ligandos receptores
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
DK0447285T3 (da) Nephtalenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem
PE55097A1 (es) Isotiazolonas
ES2149215T3 (es) Bencilaminoquinuclidinas sustituidas como antagonistas de la sustancia p.
ES2159714T3 (es) Hidroximetil-imidazodiazepinas y sus esteres.
ES2166379T3 (es) 2-aminotetralinas sustituidas.
DK202882A (da) Fremgangsmaade til fremstilling af 1-alkyl-2-aminotetralinderivater
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
DK0474517T3 (da) Hidtil ukendt anvendelse af 1alfa-hydroxyleret-19-nor-vitamin D-
GB8518658D0 (en) Medicaments
AR241180A1 (es) Compuesto de benzisoxazol que incluye esteroisomeros del mismo y formulacion herbicida que lo contiene.
YU22598A (sh) Derivati 5'-dezoksi-citidina
ES2058191T3 (es) Acidos 2-fenil-4-quinolincarboxilicos substituidos.
ES2051986T3 (es) Compuestos con actividad broncodilatadora.
ES2166838T3 (es) 6-(triazolil(3-(trifluorometil)fenil)metil)-2-quinolinonas y -quinolinationas.
ES2145480T3 (es) Amidas de acido carbamoilcarboxilico.
ES2187783T3 (es) Derivados de indolina utiles como antagonistas del receptor 5-ht-2c.
MX9204194A (es) Los compuestos de 1,2,4-oxadiazolil-fenoxialquilisoxazolas y su uso como agentes antivirales

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 260817

Country of ref document: ES